Most genetically engineered mouse models (GeMMs) of colorectal cancer are limited by tumor formation in the small intestine, a high tumor burden that limits metastasis, and the need to generate and cross mutant mice. cell line or organoid transplantation models generally produce tumors in ectopic locations-such as the subcutaneous space, kidney capsule, or cecal wall-that do not reflect the native stromal environment of the colon mucosa. Here, we describe detailed protocols to rapidly and efficiently induce site-directed tumors in the distal colon of mice that are based on colonoscopy-guided mucosal injection. these techniques can be adapted to deliver viral vectors carrying cre recombinase, crIspr-cas9 components, crIspr-engineered mouse tumor organoids, or human cancer organoids to mice to model the adenoma-carcinoma-metastasis sequence of tumor progression. the colonoscopy injection procedure takes ~15 min, including preparation. In our experience, anyone with reasonable hand-eye coordination can become proficient with mouse colonoscopy and mucosal injection with a few hours of practice. these approaches are ideal for a wide range of applications, including assessment of gene function in tumorigenesis, examination of tumor-stroma interactions, studies of cancer metastasis, and translational research with patient-derived cancers.
IntroDuctIon
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the United States, despite CRC screening programs and risk factor changes such as decreased smoking rates and increased use of aspirin. Whereas incidence in adults > 50 years has decreased by 32% since 2000, incidence in younger adults has unexpectedly increased by 22% during the same time period 1 . Observational studies in humans provide limited insights into disease biology. In vitro studies using mouse and human cultures of cancer cells and 3D organoids have greatly advanced our understanding of the mechanisms of colorectal carcinogenesis. However, unlike cell culture or organoid systems, mouse models offer the ability to study tumor initiation, tumor-stromal interactions, immune regulation of cancer, angiogenesis, and metastasis.
Modeling colon cancer in the mouse
The most commonly used mouse models of CRC are based on deletion of the Apc tumor suppressor gene 2, 3 . Loss of Apc results in stabilization and nuclear translocation of β-catenin, which drives the constitutive expression of Wnt target genes that induces dysregulated intestinal stem cell proliferation and tumor formation. These models recapitulate the histology of human adenomas, or cancer precursor lesions. Germline loss of a single Apc allele, followed by spontaneous somatic deletion of the second Apc allele (e.g., the Apc Min mouse), results in ~30-100 adenomas in the small intestine in mice between 4 and 6 months of age 4, 5 . However, sporadic CRC in humans usually presents with a single cancer in the colon; small intestinal cancer is rare. Investigators have therefore selected promoters to drive Cre recombinase expression in the colons of Apc fl/fl mice, with varying tumor numbers in the colon versus the small intestine 3 . Alternatively, adenoviral Cre recombinase can be delivered to the distal colons of Apc fl/fl mice with rectal enema (which requires abdominal surgery) 6 or a specially designed sponge 7 . A major limitation of most GEMMs of CRC is the need to generate, maintain, and cross mice with germline mutations to assess gene function in tumorigenesis.
Transplantation models offer advantages over GEMMs, including lower cost and the ability to manipulate cell lines or 3D organoid cultures in vitro. Although cell lines poorly reproduce the histology of human cancer in vivo, engrafted organoids and patient-derived xenografts closely mimic key histopathological features of human cancer 8 . Mouse tumor organoids with multiple cancer-associated mutations (i.e., Apc, Trp53, Kras, and/or Smad4) have been transplanted into the mouse flank, rectal mucosa, and inflamed colon to model CRC and liver metastasis 9, 10 . Normal human organoids have been engineered with key cancer-associated mutations using the CRISPR-Cas9 system, and then engrafted into the mouse flank, kidney capsule, and cecal wall [11] [12] [13] [14] . Furthermore, patient-derived primary CRCs can be cultured with close to 100% efficiency as organoid lines, and can then be transplanted into the mouse flank, kidney capsule, and spleen (to model liver seeding) 15 . However, transplantation into these ectopic sites does not permit the study of tumor invasion of the muscularis propria or extravasation through the colon serosa into the circulation. Other groups have transplanted human CRC cell lines into the rectal mucosa or patient-derived tumor organoids into the colon (after the induction of colitis) to model primary cancer and liver metastasis 10, 16, 17 . GEMMs and transplantation models of CRC that produce tumors in the colon are described in Table 1 . Use of colonoscopy in the establishment of mouse models of colorectal cancer Colonoscopy is the examination of the colon using an instrument containing a light source, a camera, and a working channel for tissue sampling or intervention. Colonoscopy is commonly used in clinical medicine for the detection and removal of precancerous adenomas to prevent CRC in susceptible individuals. The first reports of white-light colonoscopy in mice were by Huang et al. 18 and Wirtz et al. 19 . Since then, mouse colonoscopy has been applied for near-IR imaging [20] [21] [22] [23] , optical coherence tomography 24, 25 , chromoendoscopy (i.e., methylene blue painting of the mucosa) 26 , fluorescence 27, 28 , narrow band imaging 29 , and confocal microscopy 29 . These technologies are used to improve on white light for detection of small tumors 30 . Tumor biopsy with specialized forceps has also been described 30, 31 .
Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation
The use of colonoscopy-guided mucosal injection for CRC modeling was first reported by Zigmond et al. in 2011 , who orthotopically transplanted mouse CRC cell lines with a 30-gauge injection needle and showed that the cells successfully formed tumors in the colon 32 . Since then, another group has applied this approach to model liver metastasis from orthotopically engrafted human CRC cell lines 33 .
We recently developed mouse models of CRC and metastasis based on colonoscopy-guided mucosal injection of viral vectors or tumor organoids 34 . We improved on existing mucosal injection methods by using a 33-gauge needle and a 100-µl syringe, which offers precise site-directed injection and the formation of a mucosal 'bubble', with minimal risk of colon perforation. We applied this technique to model CRC with CRISPR-Cas9 gene editing of the colon epithelium and with orthotopic transplantation of mouse and human organoids 34 . Furthermore, we showed that these systems can be used quickly (i.e., within 2-3 months) to study putative tumor-associated genes, model the entire adenoma-carcinoma-metastasis sequence, sequentially mutate genes in established adenomas, assess tumor stem cell function, study patient-derived cancers in the native colon environment, and model normal organoid function. Our transplantation model is also uniquely suited to studying the effects of epithelial-stromal interactions in colorectal tumorigenesis. Orthotopic transplantation models offer the ability to rapidly assess gene function in CRC, model metastasis, and study patientderived tissues in vivo. In these systems, tumor organoids are engineered with desired mutations using CRISPR-Cas9 editing, which is much faster than generating germline GEMMs. Fluorescent markers and other desired features can also be easily introduced into organoids. In our models, engineered tumor organoids are engrafted into the colon mucosa via colonoscopy-guided injection. Tumors with advanced mutations spontaneously invade into the local vasculature and metastasize to the liver 34 . Other groups have reported cancer organoid transplantation without colonoscopy, either by injection into prolapsed rectal mucosa 9 or by rectal enema into mice with colitis 10, 17 . Neither of these models permit control of tumor number or location in the colon, and they require the introduction of trauma or inflammation, respectively, both of which are potential confounding factors. Both models (like our model) produce cancers in the native colon environment that invade to form liver metastases. An alternative orthotopic transplantation model is based on surgical insertion of CRISPR-Cas9-engineered human cancer organoids into the cecal wall. The resulting tumors cannot be monitored with colonoscopy, but model liver and lung metastasis in the setting of advanced mutations 13, 14 .
We developed techniques to edit cancer-associated genes in the colon epithelium using colonoscopy-guided injection of CRISPRCas9 components in lentiviral constructs 34 . Our group previously used a similar somatic gene-editing system to model lung cancer in mice 35 . An important advantage of this model is that tumors with multiple mutations can be quickly and efficiently induced in wild-type mice from any background. These tumors are histologically similar to tumors found in traditional GEMMs. In addition, our in situ gene-editing model offers the versatility of modeling spatially defined tumors with customizable lentiviral vectors that contain multiple desired components (e.g., Cre recombinase, fluorescent markers, Cas9, and multiple sgRNAs). These features are difficult to model in germline GEMMs. A limitation of this model is that reproducible lentiviral infection of colon stem cells in situ generally requires viral titers of at least 10,000 transforming units (TU)/µl. There are currently no other published in vivo genome-editing models of CRC.
Our mouse models require a mouse colonoscopy system and at least a few hours of training for mouse colonoscopy and the mucosal injection technique. Once the user knows how to operate the equipment, the injection procedure, including setup, takes ~15 min. The advantages and disadvantages of commonly used GEMMs and transplantation models of CRC, including the models discussed in this paper, are outlined in Table 1 .
Experimental design
In this article, we provide step-by-step protocols for mouse intestinal organoid generation (modified from Sato et al. 36, 37 ), lentiviral infection (modified from a retroviral transfection protocol in Koo et al. 38 ), human CRC organoid generation (modified from Fujii et al. 15 and van de Wetering et al. 39 ), and colonoscopyguided mucosal injection (modified from Zigmond et al. 32 and previously described in Roper et al. 34 and Beyaz et al. 40 ) for CRC modeling. Mouse or human intestinal organoid infection with viral vectors can be substituted with transfection 38 or electroporation 41 of plasmid DNA vectors.
Considerations in mouse selection. Ideal recipient mice for colonoscopy-guided mucosal injection are 6-to 8-weeks old. Young mice have colons that are smaller in diameter and less elastic than those of older mice, which makes the mucosal injection process more efficient. Female mice are preferred to male mice because the colons are smaller in diameter. However, we also regularly perform mucosal injection experiments in males or in mice > 8 weeks of age without difficulty. Mouse strains are chosen on the basis of the experimental design. Colon-specific Apc∆/∆ tumors are generated in Apc fl/fl mice or Apc fl/fl ;Villin CreER mice with mucosal injection of viral Cre recombinase or 4-hydroxytamoxifen, respectively. In situ gene editing is performed in wild-type mice or mice of any background using lentiviral constructs expressing a short guide RNA targeting exon 16 of Apc (sgApc) 42 and Cas9 (e.g., U6::sgApc-EFS::Cas9-P2A-GFP). Alternatively, lentiviral delivery of sgApc (with Cre recombinase) is sufficient to induce tumor formation in Rosa26 LSL-Cas9-eGFP/ + gene-targeted mice. Epithelial-specific gene editing is achieved by delivering CRISPR-Cas9 components to mice with Cas9 activity limited to Villin-expressing epithelial cells (i.e., tamoxifen-treated Rosa26 LSL-Cas9-eGFP/ + ;Villin CreER mice). Orthotopic engraftment of tumor organoids is generally performed in NOD scid gamma (NSG) or Rag2∆/∆ mice. Transplantation in syngeneic hosts is limited by a smaller tumor size and lower engraftment rate as compared with transplantation in immunodeficient hosts, most likely due to an immune response to the mucosal injection that may be overcome with multiple cancer-associated mutations (i.e., Apc/;Kras G12D/ + ;Trp53/). Human organoids are transplanted into NSG mice or Rag2∆/∆ mice. Separate colonies of control mice are not required; the same cohort of mice can be randomized to experimental or control lentivirus or transplanted with organoids from either study group.
Plasmid selection. Plasmid selection is based on the goals of the study. Tumor organoids can be generated by infection of mouse intestinal or colon organoids with U6::sgApc-EFS::Cas9-P2A-GFP lentivirus. If desired, additional genes can be edited using plasmids expressing specific sgRNAs. Alternatively, tumor organoids can be created from Rosa26 LSL-Cas9-eGFP/ + organoids by infection with lentiviral constructs expressing sgApc and Cre recombinase. These plasmids are also used for in vivo gene-editing models of CRC. EGF working solution Add 3.375 ml of distilled water with 0.375 ml of 10 µg/ml BSA to 1 mg of EGF to make 3.75 ml of a 0.3 µg/ml stock solution.
Aliquots can be stored at 20 °C for 3 months.
•
A83-01 working solution Make a 500 µM stock solution in 1× PBS. Aliquots can be stored at 20 °C for 3 months. Matrigel Thaw Matrigel on ice overnight, and then divide on ice into 500-µl or 1-ml aliquots. Aliquots can then be thawed on ice in ~1 h. Always keep on ice before use. Multiple freeze-thaw cycles do not appear to affect Matrigel performance. Avoid direct handling as much as possible, as the Matrigel will polymerize with body heat. We have observed occasional lot-to-lot variability in Matrigel viscosity. Therefore, we suggest ordering Matrigel in bulk from the same lot that you have tested. Adenoviral Cre recombinase Thaw Ad5CMV::Cre on ice, and then dilute to the desired concentration in PBS. The virus titer is provided with purchase and is usually 10 7 TU/µl. We suggest diluting to 100,000-300,000 TU/µl for rapid tumor formation within 2-4 weeks ! cautIon Adenovirus is required to be handled at BSL2. For animal studies, adenoviral vectors require animal BSL2 containment. Ethanol cleaning does not inactivate adenovirus; 10% bleach (0.5% sodium hypochlorite) should be used instead. Institutional approval is typically required for use of viral vectors in research animals. Confirm these requirements with your institution's biosafety officer.  crItIcal Adenovirus can be stored at − 80 °C for up to 1 year. Thaw only on ice, and not at room temperature. According to the manufacturer, adenoviral titer is stable for approximately three freeze-thaw cycles. We recommend making small working aliquots of ~250 µl per mouse after the initial thaw. Plasmid cloning for lentivirus production Cloning of lentiviral shuttle vectors is performed using a modular 'Gibson' assembly, as previously described 46 . 50% L-WRN conditioned medium Detailed procedures for producing 50% L-WRN conditioned medium are described in Miyoshi and Stappenbeck 47 . Briefly, grow L-WRN cells in DMEM supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM l-glutamine, 500 µg/ml hygromycin, and 500 µg/ml G418. Wash the cells with PBS, and then passage them without hygromycin and G418 into the desired number of tissue culture plates. When the cells are 90% confluent, replace the medium with ADMEM/F12 supplemented with 20% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, and 2 mM l-glutamine. Harvest the medium every day for 6 d, centrifuge at 2,000g for 15 min at room temperature to remove cells, and pass the supernatant through a 0.2-µm vacuum filter. Finally, dilute the medium at a ratio of 1:1 with ADMEM/F12 supplemented with 20% FBS, 500 U/ml penicillin, 500 µg/ml streptomycin, and 2 mM l-glutamine to produce 50% L-WRN-conditioned medium. Store the medium at 4 °C or − 20 °C for up to 3 months.  crItIcal The quality of L-WRN conditioned medium may vary depending on the source of FBS. Test different supplies and lots of FBS for L-WRN conditioned medium efficacy. The medium may be tested by organoid-forming assay with mouse intestinal crypts, or with a Wnt reporter Topflash assay, as we have previously described 48 . Infection medium Infection medium is 50% L-WRN conditioned medium + 10 µM Y-27632 + 10 mM nicotinamide + 8 µg/ml polybrene.  crItIcal Prepare fresh infection medium for each use. Infection culture medium Infection culture medium is 50% L-WRN-conditioned medium, 10 µM Y-27632, and 10 mM nicotinamide.  crItIcal Prepare fresh infection culture medium for each use. Mouse minimal medium Mouse minimal medium is Advanced DMEM/ F12, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM l-glutamine, 1× N2, and 1× B27. Store the medium at 4 °C or − 20 °C for up to 3 months. Human antibiotic solution Human antibiotic solution is 1× PBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 50 mg/ml normocin, 50 mg/ml gentamicin, and 10 µm/ml Fungin antifungal reagent. Prepare fresh human antibiotic solution for each use. Human growth medium Human growth medium is 50% L-WRN conditioned medium, 1× N2, 1× B27, 40 ng/ml EGF, 3 µM SB202190, 500 nM A83-01, 10 µM Y-27632 dihydrochloride monohydrate, 1 µM Nacetyl-l-cysteine, 10 mM nicotinamide, 10 nM human gastrin I, 100 µg/ml Primocin, and 10 µm/ml Fungin antifungal reagent. Store the medium at 4 °C or − 20 °C for up to 3 months. Human minimal medium Human minimal medium is Advanced DMEM/ F12, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM l-glutamine, 1× N2, 1× B27, and 100 µg/ml Primocin. Store the medium at 4 or − 20 °C for up to 3 months. Human trypsin Dilute 10× trypsin with PBS to make 1× human trypsin. Store the medium at 4 °C for up to 3 months. ! cautIon Lentivirus must be handled at BSL2. For animal studies, lentiviral vectors typically require animal BSL2 containment. Specific biosafety requirements may depend on the specific vector used (e.g., the use of CRISPR-Cas9 components to target tumor suppressor genes). Institutional approval is typically required for use of viral vectors in research animals. All virus-producing cells, syringes, culture plates, and filters should be treated with 10% bleach for 15 min before discarding. Lentivirus work areas should be decontaminated with 10% bleach after preparation. Confirm these requirements with your institution's biosafety officer.  crItIcal If lentivirus will be used for mucosal injection experiments within 48 h, we recommend storing the lentivirus on ice in a 4 °C cold room. If lentivirus will be used a few days or more after generation, then we suggest freezing small working aliquots, in addition to a small aliquot (~30 µl) for titering. Lentivirus can be stored at − 80 °C for up to 1 year. Thaw on ice. Avoid freeze-thaw cycles.  crItIcal Alternatives to mouse or human organoid infection with viral vectors include transfection 38 or electroporation 39 of plasmid DNA vectors.
1| Generate lentivirus using a second-generation lentiviral assembly platform involving a lentivirus shuttle vector (generated in the pLV1-5 backbone 46 ), a packaging plasmid (psPAX2), and a VSV-G-expressing envelope plasmid (pMD2.G). Transfect these three components into HEK293T cells using Mirus TransIT-LT1 transfection reagent, according to the manufacturer's protocol 49, 50 . 
2|

8|
Filter through a 0.45-µm PES filter.
9|
Concentrate using an ultracentrifuge (120,000g at 4 °C for 2 h) and then discard the supernatant into 10% bleach. Absorb excess supernatant. by inverting on paper towels for 2-3 min. Resuspend the pellet overnight in OptiMEM (50-200 µl per ultracentrifuge tube, depending on the desired concentration).  crItIcal step Concentration of lentivirus by ultracentrifugation is possible only for lentiviruses that have a VSV-G coat.  crItIcal step Avoid excessive pipetting of the virus back and forth, as this will shear the virus and reduce titer.  crItIcal Cre-expressing lentivirus is titered using GreenGo reporter cells on the basis of Cre activity, as previously described 35, 46 . Infection of these cells with viral Cre recombinase results in expression of GFP. GFP-expressing lentivirus is titered directly on GFP fluorescence in GreenGo or other cell lines.
11| Seed GreenGo cells into 96-well tissue culture plates at a density of 5,000 cells per well. (ii) Euthanize the animal according to the requirements of your animal facility. We expose the mouse to CO 2 for 1 min, followed by confirmatory cervical dislocation. After euthanasia, use dissecting scissors and forceps to remove the small intestine and/or the colon and place into 50 ml of ice-cold PBS. We typically do not include the cecum for crypt culture.  crItIcal step Tumor aggregates should be seeded densely (almost touching each other) to maximize organoid formation. (xiv) Incubate the plate at room temperature for 2 min, followed by incubation at 37° for 15 min to allow Matrigel to polymerize, and then add 650 µl of human growth medium per well of a 24-well plate. Organoids should form within 3 d. (xv) To separate tumor organoids from dead cells, mechanically dissociate Matrigel with a 1,000-µl pipette tip, centrifuge (300g for 5 min at 4 °C), decant, and then chemically dissociate Matrigel with 500-µl of cell recovery solution for 30 min on ice. Centrifuge (300g for 5 min at 4 °C), resuspend with cold PBS, centrifuge again (300g for 5 min at 4 °C), and then seed in Matrigel and human minimal medium in a 3:1 ratio. Culture in human minimal medium. (xvi) To passage CRC organoids, mechanically dissociate Matrigel, and then incubate with 500 µl of human trypsin in a 37 °C heating block for 1-2 min. Continuously agitate the sample with a 200-µl pipette tip. Organoids should be dissociated into small clumps of five to ten cells. Block trypsin with medium containing 10% FBS, centrifuge (300g for 5 min at 4 °C), wash with cold PBS, centrifuge again (300g for 5 min at 4 °C), and then resuspend in human minimal medium. Plate with Matrigel as previously described. Culture in human minimal medium. Unlike mouse tumor organoids, human CRC organoids should be maintained densely. We passage in a 1:1 ratio for two to three passages, and then 1:2 for further passages.
12|
Infection of mouse intestinal organoids • tIMInG 5 h 15|
Thaw the virus on ice, and then collect one to two wells of mouse organoids from a 24-well plate (Step 1) in 1× PBS. Mechanically dissociate the organoids with a 1,000-µl pipette tip. Vigorously dissociate the organoids by pipetting up and down for 1 min. Look at the tube periodically under a microscope to see if the organoids are broken up. The goal is to obtain small clumps of organoids of ~5-10 cells. Healthy organoids, as defined by minimal or no dead cells in the lumen, dissociate readily. Colon organoids generally require longer and more vigorous dissociation (i.e., 2 min) than do small intestinal organoids, as well as 2-3 min of chemical dissociation with TrypLE Express at 32°C.  crItIcal step Thaw viral reagents on ice 1 h before organoid infection. Avoid freeze-thaw cycles.
16|
Resuspend organoids in 500 µl of infection medium using a 1,000-µl pipette tip. 17| Add ~50,000-100,000 TU of virus to the dissociated organoids.
18|
Cover with Parafilm and balance the plates for centrifugation.
19|
Centrifuge for 1 h at 600g at 32 °C.
20|
Incubate at 37°C in a tissue culture incubator for ~4 h. For viral titers of ~10,000 TU/µl, a shorter incubation step of 2 h is sufficient and increases the viability of dissociated organoid cells.
21|
Plate infected organoids in a 1:3 ratio in Matrigel and infection culture medium. For example, one well of infected organoids should be plated into three wells to allow space for dissociated organoid cells to grow.
22|
Matrigel polymerization usually requires 2 min at room temperature, followed by 15 min at 37° in a tissue culture incubator. Then add 650 ml of infection culture medium to each well of the 24-well plate and culture in a tissue culture incubator at 37°C. The assistant is defined as the person drawing up the sample into the injection syringe (using the transfer needle) and performing sample injection. The assistant should be seated close to the operator. The length of the injection needle can be customized according to the desired positions of the operator and assistant. In the following steps, it is indicated who should perform each step.
29|
Our colonoscopy setup is shown in Figure 1a .
The required components are an air pump, air pump tubing, isoflurane, anesthesia delivery hose, anesthesia chambers, oxygen tank, image processor, image capture device, light source, light source cable, and colonoscope. Attach the air pump, light source cable, and camera head to the colonoscope. Place the mouse in a supine position under continuous anesthesia. Insert the colonoscope into the rectum. The colon will fill with air. Inspect the distal colon (approximately the distal 3 cm in an adult mouse) to verify that the colon lumen is free of stool pellets and excess water. Colonoscopy in mice has been previously described in detail 30 and this reference can be consulted for further guidance.  crItIcal step We use a pediatric urethroscope by Richard Wolf for colonoscopy and for mucosal injections (  crItIcal step The syringe must be secured tightly to the injection needle to avoid leakage of the payload. The injection needle should be held tightly by the operator while the syringe is being secured to the needle. The injection needle tip should always be visible. These steps will help avoid injury to the colon.
37|
Operator. Insert the tip of the injection needle into the mucosa of the colon (Fig. 2, supplementary Video 2) . The correct position of the injection needle is based on sight alone. As the needle exits the colonoscope anteriorly, the injection into the anterior surface of the colon should be performed. The ideal colon site is parallel to the colonoscope, not sloping down or up, with a 30° angle relative to the colon wall. Keep the endoscope close to the colon wall so that you can clearly see the needle entering the mucosa. Abort the injection procedure if the view is obstructed by bubbles, stool, water, or debris. Begin proximally (~3 cm from the anal verge) to allow space for additional injections, and then move distally for additional injections (if desired). Space the injections by at least 0.5 cm to avoid leakage of the sample into the adjacent injection site. You can flip the mouse over into the prone position to inject into the posterior surface of the colon.  crItIcal step If you feel a 'pop', then you have passed the needle through the muscularis propria and serosa. Overt pneumoperitoneum is rare because of the relatively small caliber of the needle. The overall mortality from mucosal injection is < 1%.
38|
Operator. Ask the assistant to inject a 'test' volume of ~10 µl (Fig. 2, supplementary Video 2) . The purpose of the 'test' injection is to determine if a mucosal bubble is forming or if the sample is leaking into the lumen. If no bubble and no fluid are seen, then the needle perforated the colon wall and the sample was injected into the peritoneum.
39|
Operator. If you see a small bubble form, ask the assistant to quickly inject the remaining volume. If successful, you will see a bubble form with overlying mucosa that fills most of the colon lumen (Fig. 2, supplementary Video 2) and the assistant will feel resistance to the injection. Keep the needle in the bubble for ~10 s to prevent leakage of the sample from the injection site. If unsuccessful, you will either see the sample leak into the colon lumen (if the needle was not placed into the mucosa) or not see the sample at all (if the needle passed through the colon wall). In this case, either readjust the needle (e.g., insert it slightly deeper) or identify a new location for injection at least 0.5 cm away from the prior injection site. Up to three bubbles can be placed in a typical adult mouse. Smaller volumes can also be delivered if desired.  crItIcal step The injection must overcome the inherent resistance of the colon mucosa to form a bubble. Therefore, the assistant must inject the entire payload forcefully and quickly (i.e., in < 1 s).
? troublesHootInG 40| After the procedure, place the mice in their cages with a heating lamp for warmth to recover.
tumor monitoring with colonoscopy • tIMInG 5 min or less per mouse 41| For most CRC models, tumors can be visualized with colonoscopy 4-6 weeks after initiation. Perform tumor monitoring using the Karl Storz colonoscopy system with white light, the SPIES, GFP fluorescence, and RFP (or tdTomato) fluorescence. SPIES, a version of narrow band imaging (NBI), facilitates detection of small tumors by reducing conventional white light to two 30-nm-wide spectra corresponding to blue and green light, which enhances the contrast for blood vessels 29 .
Fluorescence is useful for detecting tumors driven by GFP-or tdTomato-expressing lentiviral vectors or in mice with GFP or tdTomato expression (Fig. 3a-d (e) Inflammatory polyps in mice 6 weeks after successful colonoscopyguided mucosal injection that did not result in tumor formation. Unlike adenomas, these polyps are thin-walled and exhibit large blood vessels in a pattern similar to that of normal colon mucosa (arrows). On H&E staining, the polyps feature nondysplastic crypts and a diffuse lymphocytic infiltration. 
